AstraZeneca is conducting a Phase III study titled ‘A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol ...

India: Inhalation therapy remains a cornerstone in the treatment of obstructive, inflammatory, and infectious respiratory ...

Orbia Fluor & Energy Materials’ pharmaceutical business unit has published a new whitepaper about the industry’s ongoing transition to pressurised metered dose inhalers (pMDIs) to low global warming ...

The Airsupra inhaler reduces severe asthma attacks by 47%, combining immediate relief with anti-inflammatory action.

Professor Omar Usmani and Respiratory Effectiveness Group colleagues outline a pragmatic approach to inhaler choice and ...

Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for International Medical Cannabis International Medical sales now 57% of Total Revenue Cash Balance of $10.4 Million ...

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

MDIs, primarily as SABA or ICS, accounted for over half of inhalers dispensed to US older adults. Most insurance plans excluded sustainable alternatives for SABA/ICS. When covered, additional approval ...

This review focuses on the subgroup of patients with an asthma phenotype predisposed to poor control a with conventional treatment strategy; the rationale for a single-inhaler, triple-therapy ...

In January 2023, the FDA approved this pressurized metered-dose inhaler with a fixed-dose combination of albuterol and budesonide for use as rescue medication among patients with asthma aged 18 ...

MediPharm Labs has launched metered dose inhalers in the Canadian Adult Use & Wellness and Medical channels and expects to launch in Australia, the EU and the United Kingdom in Q3 of this year.